Cancer learns to resist them, and the options narrow.
For the hundreds of thousands of patients whose lung cancers have learned to outmaneuver the drugs designed to stop them, the space between treatment failure and death has long been a place of diminishing options. On August 28, 2025, Swiss biotech TOLREMO therapeutics announced that the FDA granted its experimental drug TT125-802 two Fast Track designations — one for EGFR-mutated and one for KRAS-G12C-mutated non-small cell lung cancer — both in patients whose tumors have already escaped prior targeted therapy. The designation does not promise a cure, but it signals that medicine is still searching, and that the search is being taken seriously.
- Lung cancer remains one of humanity's most lethal diseases, and the moment a tumor develops resistance to targeted therapy, the clock accelerates for patients who may have already exhausted their best options.
- TT125-802 enters this space with a distinct mechanism — inhibiting CBP/p300 proteins that sit upstream of cancer's survival machinery — offering a potential workaround to the resistance pathways that have defeated earlier drugs.
- Unlike other agents in its class, TT125-802 did not cause dangerous platelet drops in early trials, a safety advantage that could allow higher, more effective dosing as development continues.
- The FDA's dual Fast Track designations unlock faster regulatory dialogue and potential priority review, compressing a timeline that, for advanced cancer patients, is measured in months rather than years.
- TOLREMO's next move is to test TT125-802 in combination with the very EGFR and KRAS inhibitors patients have already failed — a strategy aimed at dismantling resistance rather than simply routing around it.
Lung cancer accounts for one in five cancer deaths in America, and the vast majority of cases are non-small cell lung cancer. About thirty percent of those tumors carry mutations in EGFR or KRAS-G12C — the kind that respond, at first, to targeted drugs. The problem is that cancers adapt. They find new pathways, and the drugs stop working.
On August 28, 2025, Swiss biotech TOLREMO therapeutics announced that the FDA had granted Fast Track designation to TT125-802 for both of these patient populations — those with EGFR-mutated and KRAS-G12C-mutated NSCLC who have progressed on prior targeted therapy. Fast Track status means the FDA recognizes a serious unmet need and commits to a more collaborative, accelerated review process.
TT125-802 is a CBP/p300 bromodomain inhibitor — a small molecule taken orally that targets proteins operating in parallel to the mutated genes oncologists have already tried to block. In early human trials presented at ASCO 2025, it demonstrated single-agent activity in solid tumors and, critically, did not cause thrombocytopenia, a platelet-depleting side effect that has constrained other drugs in its class. That cleaner safety profile may allow for higher doses.
CEO Stefanie Flückiger-Mangual described the drug's purpose directly: to block the transcriptional pathways that allow tumors to grow and evade treatment. Scientific advisor Alan Sandler pointed to the drug's selective mechanism as what sets it apart, and noted that combination studies with existing EGFR and KRAS inhibitors are planned.
TOLREMO is currently running a Phase 1 trial in patients with advanced solid tumors. The Fast Track designations will guide the company's next steps — a methodical effort to find a foothold in one of oncology's most stubborn problems.
Lung cancer kills one in five people who die of cancer in America. Of those cases, nearly nine out of ten are non-small cell lung cancer—NSCLC—and about three in ten of those carry mutations in either the EGFR or KRAS-G12C genes. These are the patients who get targeted drugs, and for a while, those drugs work. Then the cancer learns to resist them, and the options narrow.
On August 28, 2025, a Swiss biotech company called TOLREMO therapeutics announced that the FDA had granted Fast Track status to its experimental drug, TT125-802, for treating exactly these patients—those whose tumors have stopped responding to standard therapy. The company received not one but two Fast Track designations: one for EGFR-mutated lung cancer that has progressed despite prior EGFR inhibitor treatment, and another for KRAS-G12C-mutated disease that has similarly escaped initial therapy.
Fast Track designation is the FDA's way of saying a drug addresses a serious medical need where options are limited, and the agency wants to move it along faster. It means more frequent conversations between the company and regulators, and the possibility of accelerated approval or priority review if the data supports it. For patients running out of time, this matters.
TT125-802 works differently than the drugs that failed. It is a small molecule that inhibits CBP/p300, proteins that sit upstream of the cancer cell's survival machinery, operating in parallel to the mutated genes that oncologists have already targeted. The drug is taken by mouth. In early human trials presented at the American Society of Clinical Oncology meeting in 2025, it showed clinical activity as a single agent in solid tumors—meaning it worked on its own, without being paired with something else. Notably, it did not cause thrombocytopenia, a dangerous drop in platelet count that has limited other drugs in its class. This safety profile potentially allows for higher doses, which may be necessary to kill cancer cells.
Stefanie Flückiger-Mangual, the company's CEO, framed the challenge plainly: patients with EGFR- or KRAS-mutated lung cancer do eventually progress on their targeted drugs, and when they do, the medical need becomes urgent. "TT125-802 has the potential to address this challenge by blocking transcriptional pathways that drive tumor growth and treatment evasion," she said. The Fast Track designations, she added, provide an accelerated path to patients who need it.
Alan Sandler, a scientific advisor to the company, emphasized that the drug's selective mechanism and clean safety profile set it apart. "The two Fast Track designations highlight TT125-802's broad potential to provide a new approach for tackling drug resistance and tumor survival," he said, noting the company plans to test it in combination with existing oncogene-targeting drugs.
TOLREMO is currently running a first-in-human Phase 1 trial across multiple centers, enrolling patients with advanced solid tumors. The Fast Track designations will shape the company's next steps: advancing TT125-802 in combination studies with standard EGFR and KRAS inhibitors in patients whose cancers have become resistant. It is a measured, methodical approach to a problem that has no easy answer—but for now, it is a path forward.
Notable Quotes
NSCLC is a major cause of cancer-related death. While oncogene-targeting drugs improve overall survival, a significant number of patients eventually experience disease progression, representing a high unmet medical need.— Stefanie Flückiger-Mangual, CEO of TOLREMO therapeutics
TT125-802's highly selective mechanism of action and favorable safety profile without thrombocytopenia differentiate it from other agents in the class.— Alan Sandler, Scientific Advisory Board member at TOLREMO
The Hearth Conversation Another angle on the story
Why does it matter that this drug doesn't cause thrombocytopenia when other drugs in its class do?
Because it means you can give higher doses without poisoning the patient's blood. Platelet counts drop, and suddenly you're managing bleeding risk instead of treating cancer. If you can avoid that, you can push the dose up to where it actually kills tumor cells.
So this is for people whose cancer has already outsmarted one drug?
Exactly. They got an EGFR inhibitor or a KRAS inhibitor, it worked for a while, and then the cancer mutated around it or found another survival pathway. Now they're stuck. This drug targets a different lever entirely.
What does CBP/p300 actually do in a cancer cell?
It's an epigenetic regulator—it controls which genes get turned on and off. Cancer cells use it to survive and resist treatment. By blocking it, you're cutting off a fundamental survival mechanism that exists independently of the original mutation.
Fast Track sounds like a shortcut. Is it?
Not really a shortcut—more like a priority lane. The FDA still requires the same evidence, but they review it faster and talk to the company more often. It's for drugs addressing serious unmet needs. In this case, patients with drug-resistant lung cancer absolutely qualify.
When would patients actually get access to this drug?
That depends on how the Phase 1 trial goes and what the company learns. They're planning combination studies next. If those work, they'd move to Phase 2, then Phase 3. We're probably looking at several years, but the Fast Track status could compress that timeline somewhat.
What's the risk here?
The drug is new. Early data looks promising, but it's still in Phase 1. You don't know yet how it performs in larger populations, what side effects emerge at scale, or whether the benefit holds up. That's why the trials exist.